China's first self-innovated microsphere preparation, Rexinto®, was launched, using the world's leading microsphere technology to enhance the clinical benefits of schizophrenia

On March 27, Luye Pharmaceutical Group announced its self-developed new anti-schizophrenia drug-Rexinto? [Risperidone Microspheres for Injection (II)] officially launched in China.

Schizophrenia is a chronic, persistent and severe mental illness, accounting for more than half of the inpatients in psychiatric departments, and it is a mental illness that our country focuses on prevention and treatment.

Patients with schizophrenia need long-term medication, but these patients often have poor self-control ability and low medication compliance, and once the treatment is interrupted or the medication is reduced by oneself, it may lead to recurrence of the disease, making the treatment more and more difficult, and the cost of treatment will increase significantly.

Data show that 60% of patients with first-onset schizophrenia have poor medication compliance, and the recurrence rate within 5 years exceeds 80%.

From the perspective of global treatment concepts and trends, due to the therapeutic advantages of long-acting injections of antipsychotics, many domestic and foreign guidelines strongly recommend long-acting injections as an important treatment strategy to prevent recurrence.

Professor Cai Jun pointed out: "Based on the characteristics of high recurrence of schizophrenia, we advocate the early use of long-acting injections at all stages of the disease course.

Innovative microsphere preparation, unique drug release mechanism has obvious therapeutic advantages

Rexinto? (Risperidone Microspheres for Injection (II)) is an innovative microsphere preparation independently developed by Luye Pharma.

Compared with oral preparations, Recinto? The frequency of medication is significantly reduced, which can effectively improve patients' missed or forgotten medication.

"Most patients with schizophrenia have difficulty in taking oral medications every day.

In addition, compared with another commercially available drug, the first injection of Rexinto? There is no need to supplement the oral preparation at the same time, and the steady-state blood drug concentration can be reached faster than the commercially available drug.

"Recinto? After the injection, the effect is rapid, which can quickly control the patient's psychotic symptoms and quickly clear it after stopping the drug, which is more conducive to the rapid adjustment of the treatment plan according to the condition of the doctor.

Build the world's leading microsphere technology platform and continue to bring more treatment options to patients

Microsphere preparations are one of the representatives of new high-end preparations.

After more than ten years of unremitting efforts, Luye Pharma has established core key technologies including high drug loading and low burst release microsphere preparation technology, long-acting sustained-release preparations in vivo and in vitro release correlation evaluation, microsphere industrialized preparation technology and equipment, etc.

"Breaking technical barriers and building a mature and complete microsphere technology platform signifies that Luye Pharma has made a new breakthrough in the development and industrialization of microsphere technology.

It is reported that in addition to the already listed Ruixintuo? Luye Pharma has a series of microsphere products in different stages of research and development, including: injection rotigotine sustained-release microspheres (LY03003) for the treatment of Parkinson’s disease, injections for the treatment of sex hormone-dependent diseases such as prostate cancer and breast cancer Goserelin acetate sustained-release microspheres (LY01005), LY03009 for the treatment of Parkinson's disease, restless legs syndrome and other high-quality innovative drugs.

After the breakthrough in the R&D and industrialization of the microsphere technology platform, the first microsphere product, Ruixinto? The commercialization process is also accelerating.

Yao Jian said: “At present, Luye Pharma’s Neurological Division has established a professional team of more than 100 people.
We will communicate more with doctors to promote doctors’ recognition and understanding of the clinical effects of long-acting injections.
Application.
At the same time, we will also keep close contact with distributor partners to further expand the coverage and bring improved clinical benefits to patients.
"